This observation highlights the relevance of targeting SIRT1, an oncogenic deacetylase that negatively regulates p53 at lysine 382 and contributes to chemoresistance, as a promising strategy to restore apoptotic sensitivity in resistant leukemia cells. The gene discussed is TP53; the disease is leukemia.